Legend Biotech (LEGN) Misses Q4 EPS by 6c

Legend Biotech (NASDAQ: LEGN) reported Q4 EPS of ($0.40), $0.06 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $79.46 million versus the consensus estimate of $94.07 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
• Aptera Motors (SEV) Reports Q2 Loss of $0.20
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c